NBIX · Categories · Coverage
NBIX - Analyst coverage initiated
Neurocrine Biosciences Inc. (NBIX) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for NBIX
- Bernstein initiated coverage on Neurocrine Biosciences with a new price targetBernstein initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $221.00
- Wolfe Research initiated coverage on Neurocrine Biosciences with a new price targetWolfe Research initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $160.00
- Citigroup initiated coverage on Neurocrine Biosciences with a new price targetCitigroup initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $175.00
- Truist initiated coverage on Neurocrine Biosciences with a new price targetTruist initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $163.00
- Goldman initiated coverage on Neurocrine Biosciences with a new price targetGoldman initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $182.00
- Deutsche Bank initiated coverage on Neurocrine Biosciences with a new price targetDeutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Hold and set a new price target of $138.00
- Deutsche Bank initiated coverage on Neurocrine Biosciences with a new price targetDeutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $136.00
- UBS initiated coverage on Neurocrine Biosciences with a new price targetUBS initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $136.00
- Wells Fargo initiated coverage on Neurocrine Biosciences with a new price targetWells Fargo initiated coverage of Neurocrine Biosciences with a rating of Equal Weight and set a new price target of $110.00
- BMO Capital initiated coverage on Neurocrine Biosciences with a new price targetBMO Capital initiated coverage of Neurocrine Biosciences with a rating of Underperform and set a new price target of $76.00
- Raymond James initiated coverage on Neurocrine Biosciences with a new price targetRaymond James initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $163.00
- Raymond James initiated coverage on Neurocrine Biosciences with a new price targetRaymond James initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $163.00
- Raymond James initiated coverage on Neurocrine BiosciencesRaymond James initiated coverage of Neurocrine Biosciences with a rating of Outperform